TLR9 and neoplasm: Peritumoral injection of CpG oligodeoxynucleotides, a TLR-9 agonist used in clinical trials to improve immunotherapy, resulted in tumor directed migration of primed DCs that show enhanced phagocytosis, maturation and antigen presentation to T-cells.